Vendor Intelligence Report: Golden Eagle

Published 13 Jun 2026. 21-page investigative report on who is behind Golden Eagle: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 3 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Golden Eagle is a narrow, product-specific buy signal, not a broad catalog endorsement. Across 18 Finnrick lab tests, Golden Eagle has 16 pass / 2 fail — an overall pass rate of 89%. The cleaner tested product is Tirzepatide; Retatrutide carries the caution flag because the failures concentrate there, and the rest of the storefront’s peptide and injectable catalog has no Finnrick test coverage in this record. Ratings also move under stricter grading, so the headline score should be treated as directional rather than lot-release proof.

The identity work materially changes the buyer’s frame. A vendor first encountered as a Telegram seller with a China ? location resolves through Golden Peptide, a Colorado LLC footprint, professional acupuncture records, and public social-profile corroboration. The full report preserves the document trail; the key public takeaway is that the supported retail operator is domestic, while the China/Eagle Peptide lead remains an unresolved upstream-supply question rather than a proven manufacturer relationship.

Golden Eagle’s non-lab risk is channel and posture risk. The current storefront, private Telegram group, deleted TikTok handles, and prior Platinum Peptide branding create authentication friction. The site uses research-use-only language, yet the captured shop and archive show self-reconstitution and weight-loss-community signals, including bacteriostatic-water inclusion and earlier DIY-group language. No direct FDA warning letter was found, but the GLP-1 sales environment is under active scrutiny.

For buyers already considering Golden Eagle, the report argues for product-level selectivity: Tirzepatide is the more defensible current use case; Retatrutide should be treated as lot-specific and COA-dependent; untested catalog items should not inherit the GLP-1 test record.

Inside the full report:

  • Per-product pass/fail interpretation and methodology-divergence charts for Tirzepatide and Retatrutide
  • Colorado LLC, NPI registry, and social-profile identity resolution for the Golden Peptide operator
  • Wayback and certificate-transparency timeline covering Platinum Peptide, Golden Peptide, and pre-2025 domain activity
  • Telegram, TikTok, Instagram, and website-channel authentication analysis
  • RUO disclaimer comparison against bac-water inclusion, DIY-group language, and weight-loss marketing signals
  • Risk matrix covering Retatrutide consistency, source opacity, regulatory posture, and brand/channel confusion

Risk assessment

  • Retatrutide quality-consistency risk — medium: Retatrutide is the weaker tested product: 9 Finnrick tests, 7 pass / 2 fail, current rating 78.88%; tirzepatide is stronger at 9/9 pass.
  • COA and source-opacity risk — medium: No public COA archive or verified supplier records were identified; the China/Eagle broker link remains circumstantial and most catalog products are untested by Finnrick.
  • Regulatory and human-use-marketing mismatch risk — medium: RUO language conflicts with bac-water inclusion, DIY/weight-loss marketing signals and GLP-1 sales; no FDA warning letter was found.
  • Brand/channel-confusion risk — medium: Golden Eagle, Golden Peptide and prior Platinum Peptide branding coexist with a private Telegram group, deleted TikToks and no official-channel/reseller list.